TABLE 1.

Summary of adverse events occurring in greater than 10% of participants in part B (MAD)

	7.5 mg	15 mg	30 mg	60 mg	90 mg	All tolebrutinib	Placebo
Number of participants	8	8	8	8	8	40	10
Treatment‐related TEAE, N	4	2	3	2	5	16	2
Diarrhea	1	1	2	0	5	9	1
Headache	2	1	1	0	0	4	0

Abbreviations: MAD, multiple ascending dose; TEAE, treatment‐emergent adverse event.